Organization And Summary Of Significant Accounting Policies (Narrative) (Details) (USD $) Share data in Millions, except Per Share data, unless otherwise specified	12 Months Ended																			12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2011 Warrants Expiring In 2011 [Member]	Dec. 31, 2011 Warrants Expiring In 2013 [Member]	Dec. 31, 2011 Warrants Expiring In 2014 [Member]	Dec. 31, 2011 Warrants Expiring In 2016 [Member]	Dec. 31, 2011 May 2011 Convertible Senior Notes [Member]	Apr. 30, 2006 May 2011 Convertible Senior Notes [Member]	Dec. 31, 2011 May 2013 Convertible Senior Notes [Member]	Apr. 30, 2006 May 2013 Convertible Senior Notes [Member]	Dec. 31, 2011 May 2014 Convertible Senior Notes [Member]	Jul. 31, 2010 May 2014 Convertible Senior Notes [Member]	Dec. 31, 2011 May 2016 Convertible Senior Notes [Member]	Dec. 31, 2011 April 2021 Senior Unsecured Notes [Member]	Mar. 31, 2011 April 2021 Senior Unsecured Notes [Member]	Dec. 31, 2011 Convertible Senior Notes [Member]	Dec. 31, 2010 Convertible Senior Notes [Member]	Dec. 31, 2011 December 2014 Senior Unsecured Notes, December 2016 Senior Unsecured Notes, December 2021 Senior Unsecured Notes And December 2041 Senior Unsecured Notes [Member]	Dec. 31, 2011 Greater Than 120 Days Past Due [Member]	Dec. 31, 2011 Greater Than 365 Days Past Due [Member]	Dec. 31, 2011 Accounts Receivables [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Advertising expenses	$ 116,600,000	$ 116,500,000	$ 108,100,000
Conversion price of notes								$ 38.75	$ 38.75	$ 38.10	$ 38.10	$ 45.08	$ 45.08	$ 45.41
Warrants exercise price				50.80	53.90	56.76	60.10
Weighted-average shares of common stock outstanding excluded from the computation of diluted net income per share because their effect was antidilutive	21.1	22.5	17.4
Percentage of fair value of securities sold and collateralized by U.S. government securities	102.00%
Accounts receivables, amount past due																				612,400,000	250,700,000
Accounts receivable, days past due																				120	365
Total Accounts Receivable due from Greece, Italy, Portugal and Spain																						1,100,000,000
Purchase cost of royalties interest paid	525,000,000
Percentage share cost of royalty interest paid	65.00%
Percentage share cost of royalty interest by Royalty Pharma	35.00%
Prepaid royalties capitalized	341,300,000
Unamortized prepaid royalty asset	190,200,000	219,500,000
Amortized to cost of goods sold	29,300,000	25,500,000	29,900,000
Unamortized capitalized software costs	96,000,000	22,500,000
Net transaction losses	21,300,000	3,700,000	16,400,000
Carrying value of the convertible notes	2,920,000,000	3,480,000,000
Carrying value of the senior unsecured notes	7,605,734,000	2,838,573,000													992,100,000				3,690,000,000
Debt Instrument, Fair Value															1,060,000,000		3,530,000,000	3,970,000,000	3,930,000,000
Principal amount of senior notes									$ 650,000,000		$ 650,000,000		$ 1,250,000,000			$ 1,000,000,000			$ 3,700,000,000